Xenetic Biosciences financials
$2.26−3.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.5M | $0.00 | $1.2M | $436.9K | $17.1K | $0.00 | $7.6M | $3.0M |
| Gross profit | $0.00 | $0.00 | $2.5M | $0.00 | $1.2M | $436.9K | $17.1K | $0.00 | $7.6M | $3.0M |
| Gross margin | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$5.8M | -$6.7M | -$4.5M | -$8.4M | -$5.7M | -$13.9M | -$12.9M | -$7.3M | -$3.6M | -$47.4M |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M | -$10.9M | -$18.1M | -$7.3M | -$3.6M | -$58.2M |
| Net margin | — | — | −162.8% | — | −486.4% | −2493.1% | −105821.0% | — | −47.4% | −1941.4% |
| Diluted EPS | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-5.50 | $-17.00 | $-63.30 | $-96.60 | $-49.20 | $-940.80 |
| EBITDA | -$5.8M | -$6.7M | -$4.5M | -$8.4M | -$5.7M | -$4.7M | -$9.6M | -$7.3M | -$3.5M | -$47.4M |
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$5.1M | -$4.7M | -$4.3M | -$6.4M | -$6.5M | $1.5M | -$8.8M |
| Free cash flow | -$2.3M | -$2.8M | -$4.1M | -$5.1M | — | — | — | — | $1.5M | -$8.8M |
| Diluted shares | 1.7M | 1.5M | 1.5M | 1.4M | 1.0M | 0.6M | 0.3M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.9M | $6.2M | $9.0M | $13.1M | $18.2M | $11.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M | $13.2M |
| Total liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M | $964.0K |
| Shareholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M | $12.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology